More Indian Firms Dip Toes In Vaccines Segment: Just 'Opportunistic'?
Executive Summary
The vaccines segment continues to draw the interest of participants beyond those firms with a traditional core presence, with new players largely building partnered capabilities around COVID-19 inoculations. Are these merely opportunistic forays or will the competitive landscape for vaccines stand altered more widely?
You may also be interested in...
Piramal Dreams Big, Wants To Be In Top Five India-Listed Pharma
Nandini Piramal, executive director, Piramal Enterprises, discusses how things have shaped in the group's pharma business, its continuing appetite for acquisitions, efforts to de-risk the supply chain for key starting materials and the outsourcing "framework" deployed by industry.
Strides Sees COVID-19 Pills Not Impacting Vaccine Uptake
Strides’ CEO tells Scrip Merck’s molnupiravir and Pfizer’s Paxlovid are not seen impacting COVID-19 vaccine uptake as boosters and immunization for travel will drive continued demand. The Indian company expects to book Sputnik Light sales from Q4. Meanwhile, US revenue guidance of $225-250m has been pushed back by a year to FY23.
Sun Wants To Join The Biosimilars Party, In Time
India's Sun Pharma is to foray into biosimilars, targeting first approval status for “third wave” products. It trails several peers and the changed stance comes as biosimilars gain traction in markets including the US, where experts have predicted a “coming out party” in the next few years.